Gossamer Bio regains Nasdaq listing compliance

Nasdaq’s April 8, 2026 notice cited 30 consecutive business days below its $1.00 minimum bid price threshold.

Rhea-AI Filing Summary

Gossamer Bio, Inc. received a Nasdaq letter on September 25, 2026, stating that it had regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market and that the matter was closed. The company had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. It effected a 1-for-80 reverse stock split on September 10, 2026, and its common stock began trading on a split-adjusted basis on September 11, 2026.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Reverse stock split ratio: 1-for-80 Minimum bid price: $1.00 or more Noncompliance period: 30 consecutive business days

3 metrics

Reverse stock split ratio 1-for-80 Effected September 10, 2026

Minimum bid price $1.00 or more Nasdaq continued-listing requirement

Noncompliance period 30 consecutive business days Period the common stock failed to maintain the minimum bid price

Key Terms

minimum bid price requirement, continued listing, split-adjusted basis

3 terms

minimum bid price requirement regulatory

"regained compliance with the minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

continued listing regulatory

"requirement for continued listing on the Nasdaq Global Select Market"

When a stock receives a "continued listing," it means the exchange has decided the company’s shares will remain tradable on that market after a review or challenge, often because the company met certain requirements or corrective steps. For investors this matters because continued listing preserves liquidity and access to buy or sell the stock—think of it as a store passing an inspection so customers can keep shopping rather than being forced to close.

split-adjusted basis market

"began trading on a split-adjusted basis"

An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Did GOSS regain Nasdaq listing compliance?

Yes. Nasdaq notified Gossamer Bio on September 25, 2026, that it had regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market, and the matter was closed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 04:02 PM Accepted by SEC EDGAR 09/28/2026 - 04:01 PM Learn about SEC filing dates

0001728117FALSE00017281172026-09-252026-09-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2026

GOSSAMER BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38796			47-5461709
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

3115 Merryfield Row, Suite 120

San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)

(858) 684-1300

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

GOSS

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 8.01 Other Events.

On September 25, 2026, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1), and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on April 8, 2026 from the Listing Qualifications Department of Nasdaq, indicating, as previously reported, that the Company was not then in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. As previously disclosed, on September 10, 2026, the Company effected a 1-for-80 reverse stock split of its common stock, and the Company’s common stock began trading on a split-adjusted basis on the Nasdaq Global Select Market on September 11, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						GOSSAMER BIO, INC.
Date: September 28, 2026						By:			/s/ Christian Waage
									Christian Waage Executive Vice President and General Counsel

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB